Treatment Information

Back

Lung Cancer treatment details. Chemotherapy, Biologic therapy.

Kantonsspital St.Gallen, St. Gallen, Switzerland.

Survival: monthsCountry:Switzerland
Toxiciy Grade:4City/State/Province:St. Gallen
Treatments:Chemotherapy, Biologic therapyHospital:Kantonsspital St.Gallen
Drugs:Journal:Link
Date:Apr 2008

Description:

Patients:
This study involved 63 non-small-cell lung cancer patients who had not received prior chemotherapy. The median age was 62 years and 62% were male.

Treatment:
Patients were treated with a biologic therapy called gefitinib (an inhibitor of the epidermal growth factor receptor tyrosine kinase) as well as the chemotherapy agents gemcitabine and cisplatin.

Toxicities:
The most severe adverse effects were of grade 4 and included neutropenia and thrombocytopenia. Also reported were grade 3 diarrhea, fatigue, and infection.

Results:
The median overall survival was 11.5 months.

Support:
This study was supported by Astra Zeneca, makers of gefitinib (trade name: Iressa).

Correspondence: Dr. Dr G. D’Addario; email: [email protected]



Back